Adebrelimab plus chemoradiation for inoperable esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and radiation for people with early-stage esophageal cancer that cannot be surgically removed. It aims to see if this approach can shrink or control the cancer without needing an operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have squamous cell esophageal cancer in the chest area that has not spread to lymph nodes (stage T1b–T2 N0 M0).
- You cannot have surgery to remove the esophagus, or you have chosen not to have surgery.
- You have not had any prior cancer treatment for this condition (e.g., chemotherapy, radiation, or surgery).
- You are in generally good health (able to do daily activities) and have adequate organ function as shown by recent blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called adebrelimab (an immunotherapy) combined with chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery or has come back after surgery. It aims to see if the combination is safe and effective.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a combination of the immunotherapy drug adebrelimab (SHR-1316) and chemotherapy given before and after surgery for locally advanced esophageal squamous cell carcinoma that can be removed. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy before surgery for esophageal squamous cell carcinoma (a type of throat cancer). The goal is to shrink the tumor and improve outcomes before the surgical removal of the cancer.
This trial tests whether adding the immunotherapy drug adebrelimab to a short course of chemo and radiation before surgery can improve outcomes for patients with resectable esophageal cancer. It is designed for people with a specific stage of esophageal squamous cell carcinoma that has not been treated before.
This trial tests a new approach for people with a certain type of esophageal cancer. Instead of surgery right away, you would receive chemotherapy, radiation, and an immunotherapy drug called adebrelimab. After that, doctors will closely watch your cancer to see if it's gone. The goal is to avoid surgery if the treatment works well.
Hear when a new Resectable Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.